SARS-CoV-2 and COVID-19

Virus

Enveloped, POSITIVE-sense ssRNA, Coronaviridae. LARGEST RNA genome among human viruses — has PROOFREADING EXONUCLEASE (most RNA viruses lack) → LOWER mutation rate per cycle than influenza, though huge transmission scale still generated variants (Alpha, Delta, Omicron). SPIKE (S) PROTEIN: name origin (“corona”), binds ACE2 receptor (attachment+fusion), PRIMARY vaccine target (all major platforms).

Pathogenesis

Respiratory droplets+aerosols (understanding of aerosol role improved over pandemic → ventilation/masking guidance shift). ACE2 expressed: respiratory epithelium + vascular endothelium + cardiac tissue + GI tract → explains BEYOND-LUNG disease (cardiac injury, GI symptoms, coagulopathy/thrombosis all trace to broad receptor distribution).

Severe COVID pneumonia: driven substantially by DYSREGULATED HOST IMMUNE/CYTOKINE RESPONSE (“cytokine storm”), NOT just direct viral damage — explains why immunomodulatory Rx (steroids) has genuine role in SEVERE disease specifically. Coagulopathy/thrombosis (micro+macrovascular): distinctive severe COVID feature.

Clinical Manifestations

Spectrum: asymptomatic (substantial %, complicates symptom-based screening) → mild URI (fever, cough, fatigue, + ANOSMIA/AGEUSIA distinctively, less prominent in other respiratory viruses) → severe pneumonia/ARDS (minority).

Risk factors severe disease: AGE = STRONGEST predictor (even more dominant than for most other respiratory viruses), obesity, diabetes, CVD, chronic lung disease, immunosuppression.

PASC/“Long COVID”: persistent symptoms (fatigue, brain fog, dyspnea) months+ post-acute. Genuinely important, distinguishes COVID from most other acute respiratory viruses by scale/persistence.

MIS-C (Multisystem Inflammatory Syndrome in Children): RARE, DELAYED (weeks post-infection, often mild/asymptomatic initial), hyperinflammatory, persistent fever+multi-organ, resembles Kawasaki disease. Delayed immune-mediated phenomenon, not direct acute viral disease.

Laboratory Diagnosis

RT-PCR (nasopharyngeal swab): GOLD STANDARD, highly sens/spec. Ct value = rough viral load proxy. Rapid antigen test: faster/cheaper, MEANINGFULLY lower sensitivity (esp. early/low viral load) — best for screening/serial testing, not single definitive rule-out. CT chest: ground-glass opacity (characteristic but non-specific) — severity assessment, not primary diagnostic tool.

Treatment

STRATIFIED by severity/timing (same principle as HSV encephalitis, botulism, diphtheria — early appropriate intervention changes outcome):

Antivirals (nirmatrelvir-ritonavir, remdesivir): MOST effective EARLY (outpatient/early-hospitalized, at-risk for progression) — inhibit replication before immune-dysregulation phase dominates.

Corticosteroids (dexamethasone): benefit specifically in SEVERE, LATER-STAGE disease needing supplemental O2 (immune-mediated injury mechanism). NO BENEFIT/POTENTIALLY HARMFUL in early/mild disease (viral replication still dominant, not immune dysregulation) — KEY testable point: WHEN it helps, not just whether.

Supportive care (O2, ventilation) = foundational throughout severity spectrum.

Prevention — Vaccination

Notable technological milestone: mRNA vaccines (FIRST mass-deployed mRNA platform, encodes spike for host cell production/presentation).

Viral vector (modified non-replicating adenovirus delivers spike gene) + Protein subunit (purified spike protein, same logic as HBV/HPV subunit vaccines, see Vaccines topic).

ALL platforms target SPIKE — variants with spike mutations (drift-like phenomenon, but from ordinary mutation accumulation not reassortment, unsegmented genome) periodically ↓vaccine effectiveness vs INFECTION specifically, while effectiveness vs SEVERE disease/hospitalization more durable across variants.

The Virus

SARS-CoV-2 is an enveloped, positive-sense single-stranded RNA virus of the Coronaviridae family — genuinely the largest RNA genome known among human viruses, which is mechanistically significant, since replicating such a large RNA genome accurately requires a viral proofreading exonuclease most other RNA viruses lack, giving coronaviruses a somewhat lower mutation rate per replication cycle than, say, influenza — though SARS-CoV-2’s sheer global transmission scale during the pandemic still generated substantial cumulative genetic diversity and the variant lineages (Alpha, Delta, Omicron, and others) that shaped the pandemic’s successive waves. The virus’s name-giving feature — a corona (“crown”) of club-shaped spike (S) protein projections studding the envelope surface — is also its primary functional and immunological target: the spike protein mediates attachment to the host ACE2 receptor and subsequent membrane fusion, and is the antigen targeted by essentially every major COVID-19 vaccine platform.

Pathogenesis

Transmission is predominantly via respiratory droplets and aerosols (with relative contribution shifting over the pandemic as understanding of aerosol transmission specifically improved, prompting revised guidance toward better ventilation and masking beyond simple droplet precautions). The spike protein’s ACE2 binding explains the virus’s tissue tropism directly, since ACE2 is expressed not only on respiratory epithelium but also on vascular endothelium, cardiac tissue, and the GI tract — a genuinely important mechanistic explanation for COVID-19’s noted capacity to cause disease well beyond the lungs alone (cardiac injury, GI symptoms, coagulopathy/thrombosis all trace back to this same broad receptor distribution).

Severe COVID-19 pneumonia is driven substantially by a dysregulated host immune/cytokine response (“cytokine storm” in its more extreme form) rather than by direct viral cytopathic damage alone — a genuinely important pathophysiological point, since it is exactly why immunomodulatory therapy (corticosteroids, below) has a genuine, evidence-based role in severe disease specifically, in a way that would seem counterintuitive for a viral infection if the illness were purely a matter of direct viral tissue destruction. Coagulopathy and thrombosis (both microvascular and macrovascular) are a genuinely distinctive, well-documented feature of severe COVID-19, contributing meaningfully to the multi-organ complications seen in critical illness.

Clinical Manifestations

Presentation ranges across a genuine spectrum from asymptomatic infection (a substantial proportion of all infections, with real implications for the difficulty of controlling transmission through symptom-based screening alone) through mild upper-respiratory illness (fever, cough, fatigue, and, genuinely distinctively for a substantial subset of patients, anosmia/ageusia — loss of smell/taste, a real, specific clinical clue that was notably less prominent in most other common respiratory viral infections) to severe pneumonia and acute respiratory distress syndrome (ARDS) in a minority. Risk factors for severe disease — advancing age (the single strongest predictor), obesity, diabetes, cardiovascular disease, chronic lung disease, and immunosuppression — mirror, in broad strokes, the risk-factor pattern seen for severe influenza, though with age representing an even more dominant, graded risk factor for COVID-19 specifically than for most other respiratory viral infections covered in this curriculum.

Post-acute sequelae of COVID-19 (PASC, “long COVID”) — persistent symptoms (fatigue, cognitive impairment/“brain fog,” dyspnoea, and others) extending well beyond the acute infection, in some patients for months to longer — represents a genuinely important, still incompletely understood chronic complication, distinguishing COVID-19 from most other acute respiratory viral infections covered in this curriculum by the scale and persistence of this long-term symptom burden. Multisystem inflammatory syndrome in children (MIS-C) is a rare, delayed, hyperinflammatory complication occurring weeks after initial (often mild or even asymptomatic) infection in children, presenting with persistent fever, multi-organ involvement, and features that can resemble Kawasaki disease — a genuinely distinctive paediatric complication worth remembering as a delayed, immune-mediated phenomenon rather than direct acute viral disease.

Laboratory Diagnosis

RT-PCR of a nasopharyngeal or similar respiratory swab remains the diagnostic gold standard, highly sensitive and specific, with cycle threshold (Ct) values sometimes used as a rough, imperfect proxy for relative viral load. Rapid antigen tests offer faster turnaround and lower cost, at the expense of meaningfully lower sensitivity, particularly in early or low-viral-load infection — genuinely most useful for quick screening and repeat/serial testing strategies rather than as a single definitive rule-out test, given the real risk of a false negative on any single antigen test. Chest imaging (CT, showing the characteristic though non-specific ground-glass opacity pattern in more severe disease) supports clinical assessment of severity rather than serving as a primary diagnostic tool.

Treatment

Management is genuinely stratified by disease severity and timing, mirroring the broader principle (seen elsewhere in this curriculum, e.g. HSV encephalitis, botulism, diphtheria) that early, disease-course-appropriate intervention meaningfully changes outcome: antivirals (nirmatrelvir-ritonavir, remdesivir) are most effective when given early in the disease course, targeted at outpatients/early-hospitalized patients at risk of progression, working by directly inhibiting viral replication before the disease has progressed to the immune-dysregulation-dominated later phase. Corticosteroids (dexamethasone), by contrast, have their proven benefit specifically in more severe, later-stage disease requiring supplemental oxygen — reflecting the immune-mediated injury mechanism described above — and are, notably, of no benefit and potentially harmful in early/mild disease, where viral replication rather than immune dysregulation is still the dominant process, a genuinely important, specifically testable point about when a given intervention actually helps rather than simply whether it helps in COVID-19 generally. Supportive care (oxygen, ventilatory support as needed) remains foundational throughout the severity spectrum.

Prevention: Vaccination

COVID-19 vaccination represents a genuinely notable technological milestone in this curriculum: mRNA vaccines (the first mRNA-platform vaccines ever deployed at mass scale, encoding the spike protein for the host’s own cells to produce and present to the immune system) achieved rapid, large-scale deployment alongside more conventional platforms — viral vector vaccines (using a modified, non-replicating adenovirus to deliver the spike gene) and protein subunit vaccines (delivering purified spike protein directly, the same subunit logic covered under Vaccines and Immunoprophylaxis for hepatitis B and HPV). All platforms target the spike protein specifically, which is exactly why viral variants carrying substantial spike-protein mutations (the same antigenic-drift-type phenomenon covered under Influenza, though arising from ordinary RNA-virus mutation accumulation rather than reassortment, since SARS-CoV-2’s genome is unsegmented) have periodically reduced vaccine effectiveness against infection specifically, even while effectiveness against severe disease/hospitalization has generally remained more durable across variants.